Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Volume effectif minimal de co-chargement de cristalloïdes pour prévenir l'hypotension induite par la rachianesthésie lors d'une césarienne

16 novembre 2026 mis à jour par: Seoul National University Hospital

Détermination du volume effectif minimal de co-chargement cristalloïde pour prévenir l'hypotension induite par l'anesthésie rachidienne lors de la césarienne : étude par conception de pièce biaisée

The goal of this clinical trial is to find the minimum effective volume of IV crystalloid that should be given with phenylephrine to prevent hypotension caused by spinal anesthesia in healthy, term pregnant adults having elective cesarean delivery.

The main questions are:

What is the minimum effective volume (MEV90, mL/kg) of crystalloid co-loading that prevents spinal-anesthesia-induced hypotension in ≥90% of participants?

What maternal side effects and newborn outcomes occur with this strategy (e.g., nausea/vomiting, need for extra vasopressors, total fluids/blood loss, Apgar scores, and umbilical cord blood gases)?

There is no separate comparison group; this is a single-arm, adaptive dose-finding study.

Participants will:

Receive a predefined volume of IV crystalloid over ~10 minutes during spinal anesthesia while phenylephrine is infused. Have blood pressure and symptoms monitored; receive rescue treatment if needed. Allow the next participant's fluid volume to be adjusted based on whether hypotension occurred (biased-coin design). Be followed through postoperative day 2 for maternal and newborn outcomes.

Aperçu de l'étude

Type d'étude

Interventionnel

Inscription (Estimé)

45

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

      • Seoul, Corée du Sud
        • Recrutement
        • Seoul National University Hospital

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

19 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Oui

Sexes éligibles pour l'étude

Femelle

La description

Inclusion Criteria:

  • Pregnant adults ≥19 years scheduled for elective cesarean delivery under spinal anesthesia
  • Term pregnancy (≥37 weeks' gestation)

Exclusion Criteria:

  • Emergency cesarean delivery
  • Hypertensive disorders of pregnancy (preeclampsia/eclampsia) or hypertension
  • Multiple gestation
  • Body weight <50 kg or BMI >35 kg/m²
  • Renal impairment or eGFR ≤90 mL/min/1.73 m²
  • Heart failure or other heart disease
  • History of bronchial asthma or other pulmonary disease

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: La prévention
  • Répartition: N / A
  • Modèle interventionnel: Affectation à un seul groupe
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Crystalloid Co-Loading

Participants undergo spinal anesthesia for elective cesarean delivery. Immediately after intrathecal injection, a predefined volume of balanced crystalloid (co-loading) is infused over ~10 minutes while a prophylactic phenylephrine infusion is initiated per protocol. The crystalloid volume for each successive participant is adjusted using a biased-coin up-and-down algorithm to identify the minimum effective volume that prevents spinal-anesthesia-induced hypotension in ≥90% of patients (MEV90, mL/kg). Blood pressure is monitored frequently; rescue phenylephrine and/or fluids are permitted to maintain predefined blood pressure ranges. Maternal adverse events and neonatal outcomes are recorded through postoperative day 2.

Balanced crystalloid is infused intravenously immediately after intrathecal injection as a co-load. A predefined volume (mL/kg) is administered over ~10 minutes. The volume for successive participants is adapted by a biased-coin up-and-down algorithm to estimate the minimum effective volume (MEV90) that prevents spinal-anesthesia-induced hypotension. Rescue fluids are allowed per protocol.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Minimum Effective Volume (MEV90) of Intravenous Crystalloid Co-Loading (mL/kg)
Délai: From intrathecal injection (start of spinal anesthesia) to end of surgery

The smallest crystalloid co-loading dose (mL/kg) that prevents spinal-anesthesia-induced hypotension in ≥90% of participants when given with prophylactic phenylephrine.

From intrathecal injection (start of spinal anesthesia) to end of surgery

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Incidence of intraoperative hypotension (mmHg)
Délai: From intrathecal injection to end of surgery

Hypotension is defined as a drop in systolic blood pressure (SBP) to < 80% of the participant's baseline SBP (mmHg). Baseline SBP is the mean of the last three ward SBP measurements obtained before operating room admission.

From intrathecal injection to end of surgery
Incidence of intraoperative hypertension (mmHg)
Délai: From intrathecal injection to end of surgery

Hypertension is defined as any occurrence of systolic blood pressure (SBP) > 120% of baseline SBP (mmHg) after spinal anesthesia. Baseline SBP is the mean of the last three ward SBP measurements obtained before operating room admission.

From intrathecal injection to end of surgery
Additional bolus phenylephrine requirement
Délai: From intrathecal injection to end of surgery

Administration of rescue phenylephrine bolus in addition to the protocolized prophylactic phenylephrine infusion to treat or prevent hypotension after spinal anesthesia. Hypotension is defined as SBP < 80% of baseline SBP (mmHg) or MAP < 65 mmHg. Baseline SBP is the mean of the last three ward SBP measurements obtained before operating room admission. When hypotension occurs, phenylephrine 100 µg is administered as an IV bolus to restore blood pressure. The outcome is recorded as number of phenylephrine boluses.

From intrathecal injection to end of surgery
Total Phenylephrine Dose (µg)
Délai: From intrathecal injection to end of surgery

Total intraoperative phenylephrine dose administered after spinal anesthesia, defined as the sum of the prophylactic infusion dose and all rescue bolus doses. he prophylactic infusion starts at 1,500 µg/h and the infusion rate is reduced if systolic blood pressure (SBP) exceeds 120% of baseline SBP (mmHg). Baseline SBP is the mean of the last three ward SBP measurements obtained before operating room admission. Rescue bolus protocol: phenylephrine 100 µg IV per hypotensive episode (SBP < 80% of baseline SBP [mmHg] or MAP < 65 mmHg), repeated as needed. Dose will be abstracted from the anesthesia record (infusion rate × time plus boluses) and summarized in micrograms (µg).

From intrathecal injection to end of surgery
Estimated blood loss (mL)
Délai: From skin incision to end of surgery

Calculated as (suction canister volume - irrigation volume) + gravimetric estimate of soaked sponges/drapes (1 g ≈ 1 mL). For cesarean delivery, amniotic fluid is excluded.

From skin incision to end of surgery
Incidence of Maternal Nausea Associated With Hypotension
Délai: From intrathecal injection to end of surgery

Occurrence of nausea temporally associated with hypotension after spinal anesthesia. Recorded as yes/no (≥1 episode) and number of episodes.

From intrathecal injection to end of surgery
Incidence of Maternal Vomiting Associated With Hypotension
Délai: From intrathecal injection to end of surgery

Occurrence of vomiting temporally associated with hypotension after spinal anesthesia. Recorded as yes/no (≥1 episode) and number of emetic events.

From intrathecal injection to end of surgery
Incidence of Maternal Dizziness/Lightheadedness Associated With Hypotension
Délai: From intrathecal injection to end of surgery

Occurrence of dizziness/lightheadedness temporally associated with hypotension after spinal anesthesia. Recorded as yes/no (≥1 episode) and number of episodes.

From intrathecal injection to end of surgery
Neonatal Apgar score at 1Minute
Délai: At 1 minute after birth

The Apgar score (range 0-10) assessed 1 minute after birth by clinical staff according to standard practice. It is the sum (0-2 each) of heart rate, respiratory effort, muscle tone, reflex irritability, and skin color. Recorded as the total score (0-10) and, if available, the five component scores.

At 1 minute after birth
Neonatal Apgar Score at 5 Minutes
Délai: At 5 minutes after birth

The Apgar score (range 0-10) assessed 5 minutes after birth by clinical staff according to standard practice. It is the sum (0-2 each) of heart rate, respiratory effort, muscle tone, reflex irritability, and skin color. Recorded as the total score (0-10) and, if available, the five component scores.

At 5 minutes after birth
Umbilical Arterial pH
Délai: At delivery (immediately after birth)

Umbilical cord arterial blood gas pH obtained immediately after birth from a double-clamped cord segment and analyzed per routine laboratory practice.

At delivery (immediately after birth)
Umbilical Arterial Base Excess (mmol/L)
Délai: At delivery (immediately after birth)

Umbilical cord arterial blood gas base excess measured immediately after birth from a double-clamped cord segment, processed per routine laboratory practice.

At delivery (immediately after birth)
Pulmonary edema
Délai: Through postoperative day 2

New-onset pulmonary edema within 48 hours after surgery, defined by physician diagnosis supported by clinical findings (e.g., dyspnea, crackles) and/or objective evidence (e.g., new supplemental oxygen requirement or SpO₂ ≤ 92% on room air, chest imaging consistent with interstitial/alveolar edema). Record as yes/no (≥1 event).

Through postoperative day 2
Clinically Significant Generalized Edema
Délai: Through postoperative day 2

Generalized pitting edema present within 48 hours after surgery, defined by ≥1 of the following objective criteria (excluding localized, surgical-site-limited edema):

(A) Physical exam: pitting grade ≥2+ in ≥2 anatomic regions (e.g., bilateral pretibial/ankle, hands/forearms, sacral, or periorbital), using the standard indentation scale - 2+: ~4 mm pit, brief rebound; 3+: ~6 mm pit, 10-60 s rebound; 4+: ~8 mm pit, >60 s rebound.

(B) Anthropometry: body weight increase ≥2% (or ≥2 kg) from the preoperative baseline or bilateral mid-calf circumference increase ≥2 cm from baseline.

(C) Therapeutic criterion: initiation or escalation of diuretic therapy (e.g., IV/PO loop diuretic) for generalized edema as judged by the treating clinician.

Recorded as yes/no (≥1 criterion met)

Through postoperative day 2
Acute Heart Failure
Délai: Through postoperative day 2

New diagnosis of acute heart failure within 48 hours after surgery, characterized by symptoms/signs (e.g., dyspnea, orthopnea, pulmonary congestion), objective evidence (e.g., chest radiographic congestion, elevated BNP/NT-proBNP if available, or echocardiographic findings), and requirement for treatment (e.g., IV diuretics, vasodilators, inotropes, or noninvasive ventilation). Record as yes/no (≥1 event).

Through postoperative day 2

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Hansol Kim, Seoul National University Hospital

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

11 janvier 2026

Achèvement primaire (Estimé)

31 mai 2027

Achèvement de l'étude (Estimé)

30 juin 2027

Dates d'inscription aux études

Première soumission

14 décembre 2025

Première soumission répondant aux critères de contrôle qualité

30 décembre 2025

Première publication (Réel)

7 janvier 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

19 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

16 novembre 2026

Dernière vérification

1 octobre 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • 2508-038-1665

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner